Research progress of antibody-drug conjugates therapy for HER2-low expressing gastric cancer

Gastric cancer (GC) is a highly fatal malignant tumor in the world. Most of the patients are in an unresectable state when they have symptoms. Systemic treatment is the primary treatment for advanced patients. Among them, the Human epidermal growth factor receptor 2 (HER2) is an important therapeuti...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Minghui, Liang, Yangyueying, Li, Longhui, Zhao, Lu, Kong, Fanming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860488/
https://www.ncbi.nlm.nih.gov/pubmed/36652760
http://dx.doi.org/10.1016/j.tranon.2023.101624

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9860488/
https://www.ncbi.nlm.nih.gov/pubmed/36652760
http://dx.doi.org/10.1016/j.tranon.2023.101624

Ejemplares similares